ARTICLE | Targets & Mechanisms
CAR Ts can move well beyond cancer, but will need to go allogeneic first
CAR Ts could move into autoimmunity, infections and more, if researchers can solve the allogeneic question.
October 11, 2019 2:01 AM UTC
Updated on Feb 14, 2020 at 1:53 AM UTC
Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety and commercial barriers that still haven’t been sorted out in cancer.
The critical advance is for the technology to come off-the-shelf, and the risks of neurotoxicity and cytokine release syndrome to be mitigated. ...